Published in Virchows Arch on July 01, 2005
Advanced colorectal polyps with the molecular and morphological features of serrated polyps and adenomas: concept of a 'fusion' pathway to colorectal cancer. Histopathology (2006) 1.78
Serrated polyps of the colorectum: is sessile serrated adenoma distinguishable from hyperplastic polyp in a daily practice? Virchows Arch (2007) 1.15
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch (2006) 0.99
Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population. Int J Colorectal Dis (2011) 0.97
Risk factors for serrated polyps of the colorectum. Dig Dis Sci (2014) 0.96
Clinicopathologic distribution of KRAS and BRAF mutations in a Chinese population with colorectal cancer precursor lesions. Oncotarget (2016) 0.81
Inflammatory response in serrated precursor lesions of the colon classified according to WHO entities, clinical parameters and phenotype-genotype correlation. J Pathol Clin Res (2016) 0.78
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res (2002) 4.46
BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut (2004) 4.06
Morphologic reappraisal of serrated colorectal polyps. Am J Surg Pathol (2003) 3.59
BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. Cancer Res (2003) 3.39
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours. J Pathol (2004) 3.08
BRAF mutations in papillary carcinomas of the thyroid. Oncogene (2003) 2.94
DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? J Clin Pathol (1999) 2.78
BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene (2003) 2.56
BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res (2003) 2.27
Phenotypic and molecular characteristics of hyperplastic polyposis. Gastroenterology (2000) 1.86
Serrated route to colorectal cancer: back street or super highway? J Pathol (2001) 1.73
BRAF and KRAS Mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol (2004) 1.71
High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut (1997) 1.61
Hyperplastic polyps and DNA microsatellite unstable cancers of the colorectum. Histopathology (2000) 1.57
Hyperplastic (serrated) polyps of the colorectum: relationship of CpG island methylator phenotype and K-ras mutation to location and histologic subtype. Am J Surg Pathol (2004) 1.30
Mutations of BRAF are associated with extensive hMLH1 promoter methylation in sporadic colorectal carcinomas. Int J Cancer (2004) 1.28
The serrated neoplasia pathway. Pathology (2002) 1.25
Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol (2005) 1.24
Infrequent K-ras codon 12 mutation in serrated adenomas of human colorectum. Gut (1998) 1.19
Histopathological and clinical evaluation of serrated adenomas of the colon and rectum. Mod Pathol (2003) 1.15
Serrated adenoma and colorectal cancer. J Pathol (1999) 1.04
A multistep model for ovarian tumorigenesis: the value of mutation analysis in the KRAS and BRAF genes. J Pathol (2004) 1.02
Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene (2004) 1.02
Analysis of K-ras codon 12 mutation in flat and nodular variants of serrated adenoma in the colon. Dis Colon Rectum (2003) 0.79
Progress in gastrointestinal pathology in the genetic era. Pathology (2002) 0.75
Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol (2011) 4.11
Low-level microsatellite instability in most colorectal carcinomas. Cancer Res (2002) 2.87
Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem (2001) 2.03
Multiple gastrointestinal stromal tumors: Clinicopathologic and genetic analysis of 12 patients. Am J Surg Pathol (2007) 2.02
Paricalcitol attenuates cyclosporine-induced kidney injury in rats. Kidney Int (2010) 1.92
Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem (2001) 1.85
Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology (2008) 1.78
Current Trends of the Incidence and Pathological Diagnosis of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) in Korea 2000-2009: Multicenter Study. Cancer Res Treat (2012) 1.76
Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep (2011) 1.66
Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys (2005) 1.66
Host inflammatory response predicts survival of patients with Epstein-Barr virus-associated gastric carcinoma. Gastroenterology (2010) 1.55
Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut (2013) 1.49
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. Hepatology (2005) 1.48
Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer (2013) 1.43
Changes in the signal- and contrast-to-noise ratios of hepatocellular carcinomas on gadoxetic acid-enhanced dynamic MR imaging. Eur J Radiol (2012) 1.42
Filiform serrated adenoma is an unusual, less aggressive variant of traditional serrated adenoma. Pathology (2012) 1.42
Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg (2005) 1.39
The stem cell population of the human colon crypt: analysis via methylation patterns. PLoS Comput Biol (2007) 1.38
Lysophosphatidylcholine as a death effector in the lipoapoptosis of hepatocytes. J Lipid Res (2007) 1.37
Clinical significance of signet-ring cells in colorectal mucinous adenocarcinoma. Mod Pathol (2008) 1.33
High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One (2012) 1.32
Liver X receptor mediates hepatitis B virus X protein-induced lipogenesis in hepatitis B virus-associated hepatocellular carcinoma. Hepatology (2009) 1.29
The prognostic significance of tumor-associated stroma in invasive breast carcinoma. Tumour Biol (2012) 1.27
MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol (2013) 1.25
Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol (2005) 1.24
Polypoid arteriovenous malformation of colon mimicking inflammatory fibroid polyp. J Gastroenterol (2004) 1.23
Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am J Surg Pathol (2011) 1.23
Frequent CpG island methylation in precursor lesions and early gastric adenocarcinomas. Oncogene (2004) 1.22
Primary central nervous system lymphoma presenting as an acute massive intracerebral hemorrhage: case report with immunohistochemical study. Surg Neurol (2008) 1.22
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. J Korean Med Sci (2010) 1.21
Diagnosis of gastric epithelial neoplasia: Dilemma for Korean pathologists. World J Gastroenterol (2011) 1.20
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. Virchows Arch (2005) 1.20
Gastrointestinal stromal tumors in Koreans: it's incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci (2005) 1.20
Hepatic visceral larva migrans of Toxocara canis: CT and sonographic findings. AJR Am J Roentgenol (2006) 1.19
Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long-term results and prognostic factors. Ann Surg Oncol (2007) 1.15
Combined hepatectomy and radiofrequency ablation for multifocal hepatocellular carcinomas: long-term follow-up results and prognostic factors. Ann Surg Oncol (2007) 1.14
Clinical practice guideline for accurate diagnosis and effective treatment of gastrointestinal stromal tumor in Korea. Cancer Res Treat (2012) 1.14
Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease. AJR Am J Roentgenol (2011) 1.13
Genetic classification of colorectal cancer based on chromosomal loss and microsatellite instability predicts survival. Clin Cancer Res (2002) 1.13
Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am J Pathol (2002) 1.12
Glomus tumor of the stomach: a clinicopathologic analysis of 10 cases and review of the literature. Gut Liver (2012) 1.12
Mutations of beta-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int (2005) 1.11
High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One (2012) 1.09
Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology (2012) 1.09
Clinicopathologic analysis of fine needle aspiration cytology of the thyroid. A review of 1,613 cases and correlation with histopathologic diagnoses. Acta Cytol (2003) 1.08
The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer (2011) 1.08
Current trends in the epidemiological and pathological characteristics of gastrointestinal stromal tumors in Korea, 2003-2004. J Korean Med Sci (2010) 1.08
HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling. Mol Cancer (2010) 1.08
Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Infect Dis (2013) 1.07
PKCtheta expression in gastrointestinal stromal tumor. Mod Pathol (2006) 1.05
Small submucosal tumors of the stomach: differentiation of gastric schwannoma from gastrointestinal stromal tumor with CT. Korean J Radiol (2012) 1.04
Ovarian neuroendocrine carcinoma, non-small cell type, associated with serous carcinoma. Gynecol Oncol (2007) 1.03
Analysis of fine needle aspiration cytology of the breast: a review of 1,297 cases and correlation with histologic diagnoses. Acta Cytol (2004) 1.03
Assessment of DNA methylation for the detection of cervical neoplasia in liquid-based cytology specimens. Gynecol Oncol (2010) 1.03
Renoprotective effects of paricalcitol on gentamicin-induced kidney injury in rats. Am J Physiol Renal Physiol (2009) 1.02
Gastroenteropancreatic neuroendocrine tumors: incidence and treatment outcome in a single institution in Korea. Asia Pac J Clin Oncol (2011) 1.02
Prognostic stratification of high-risk gastrointestinal stromal tumors in the era of targeted therapy. Ann Surg (2008) 1.01
Micropapillary carcinoma of stomach: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol (2010) 1.01
Primary testicular osteosarcoma with hydrocele. Virchows Arch (2004) 1.00
Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas. Mod Pathol (2012) 1.00
Primary large cell neuroendocrine carcinoma of the urinary bladder. Pathol Int (2006) 1.00
Plexiform angiomyxoid myofibroblastic tumor of the stomach: report of two cases and review of the literature. Korean J Pathol (2012) 0.99
Gastric adenocarcinoma of fundic gland type: report of three cases. Korean J Pathol (2012) 0.98
P21-activated kinase 4 overexpression in metastatic gastric cancer patients. Transl Oncol (2011) 0.97
Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy. Clin Cancer Res (2008) 0.97
Expression of activated signal transducer and activator of transcription 3 predicts poor clinical outcome in gastric adenocarcinoma. APMIS (2009) 0.97
Enteropathy-associated T-cell lymphoma--a clinicopathologic and array comparative genomic hybridization study. Hum Pathol (2010) 0.96
Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma. Lab Invest (2011) 0.96
Composite glandular-endocrine cell carcinomas of the stomach: clinicopathologic and methylation study. APMIS (2005) 0.96
Risk factors of lymph node metastasis in T1 esophageal squamous cell carcinoma. J Gastroenterol Hepatol (2007) 0.95
Comparison of four immunohistochemical tests and FISH for measuring HER2 expression in gastric carcinomas. Pathology (2012) 0.95
Mucinous gastric cancer presents with more advanced tumor stage and weaker β-catenin expression than nonmucinous cancer. Ann Surg Oncol (2010) 0.95
Brain tumor invasion model system using organotypic brain-slice culture as an alternative to in vivo model. J Cancer Res Clin Oncol (2002) 0.94
Preparation of poly(DL-lactide-co-glycolide) microspheres encapsulating all-trans retinoic acid. Int J Pharm (2003) 0.94
SPIO-enhanced MRI findings of well-differentiated hepatocellular carcinomas: correlation with MDCT findings. Korean J Radiol (2009) 0.93
Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man. Pathol Int (2003) 0.93
Inflammatory myofibroblastic tumor of the kidney misdiagnosed as renal cell carcinoma. J Korean Med Sci (2009) 0.93
Hexavalent chromium-induced apoptosis of granulosa cells involves selective sub-cellular translocation of Bcl-2 members, ERK1/2 and p53. Toxicol Appl Pharmacol (2011) 0.93
Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis. Cancer Biol Ther (2008) 0.93
HER2-positive gastric cancer with concomitant MET and/or EGFR overexpression: a distinct subset of patients for dual inhibition therapy. Int J Cancer (2014) 0.93
Renal cell carcinoma in South Korea: a multicenter study. Hum Pathol (2004) 0.93
Scrotal primary lipoma with unusual clinical appearance in newborn. Urology (2009) 0.92
Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma. J Clin Invest (2014) 0.92
Transcriptional regulation of the interleukin-11 gene by oncogenic Ras. Carcinogenesis (2012) 0.92
Microsatellite instability at a tetranucleotide repeat in type I endometrial carcinoma. J Exp Clin Cancer Res (2008) 0.92
Mesenchymal hamartomas of the liver: comparison of clinicopathologic features between cystic and solid forms. J Korean Med Sci (2006) 0.92